Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Columbia Launches Clinical Cancer Exome and Transcriptome Test

Columbia Launches Clinical Cancer Exome and Transcriptome Test

Jun 25, 2014
|
Julia Karow
Premium

NEW YORK (GenomeWeb) – A clinical cancer whole-exome and transcriptome sequencing test recently launched by Columbia University's Laboratory of Personalized Genomic Medicine promises to impact the treatment of cancer patients.

The new test was developed as part of a wider effort to incorporate personalized medicine approaches into Columbia's pediatric oncology program, according to Andrew Kung, chief of the division of pediatric hematology, oncology, and stem cell transplantation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

A Start

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

Just Go 'Round the CDC

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

Student Visa Directive Rescinded

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

Cell Studies on Blood Features of Severe COVID-19 Cases, Infection-Related Phosphorylation Shifts, More

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.